The Myb proto-oncogene is a transcription factor (consensus binding sequence 5 0 -PyAACG/TG-3 0 ; Biedenkapp et al., 1988) that plays a key role in hemopoiesis (Oh and Reddy, 1999) . c-Myb is expressed predominantly in hemopoietic tissues, although expression is also observed in several nonhemopoietic cell types (Thompson and Ramsay, 1995) . A number of studies have demonstrated that c-Myb plays an important role in cellular proliferation and in the maintenance of cells in an immature, undifferentiated state (reviewed in Weston, 1998) . Myb has also been shown to be involved in regulating apoptosis in some systems (Frampton et al., 1996; Taylor et al., 1996; Hogg et al., 1997) . Overexpression of activated or normal forms of c-Myb has been shown to induce cellular transformation (Ferrao et al., 1995; Fu and Lipsick, 1997) . Transformation by Myb requires, and to some extent correlates with, its transforming capacity, suggesting that the ability of Myb to transform is dependent on the transactivation of certain critical genes (Lane et al., 1990; Hu et al., 1991; Kanei-Ishii et al., 1992) . Thus, the identification of genes that are regulated by Myb in vivo (Myb target genes) is essential for understanding how activated forms of Myb are able to facilitate cellular transformation, and will also provide insight into how Myb controls the proliferation/differentiation program of normal cells.
To date, a number of Myb target genes have been identified (reviewed in Ness, 1996) , and several of these, such as c-myc (Evans et al., 1990; Nakagoshi et al., 1992; Schmidt et al., 2000) , cdc2 (Furukawa et al., 1990) and cyclin A1 (Muller et al., 1999) clearly play roles in cellular proliferation. However, as we have discussed previously (Bartley et al., 2001) , there is reason to believe that other Myb target genes remain to be identified.
In order to do this, we have utilized both cDNA array screening and PCR-based subtractive hybridization in conjunction with a conditionally Myb-transformed cell line, ERMYB (Hogg et al., 1997) . This cell line was derived by transforming murine fetal liver cells with an activated form of Myb fused to the ligand-binding domain of the human estrogen receptor. Consequently, Myb is only active in the presence of estrogen, and estrogen withdrawal results in terminal granulocytemacrophage differentiation. The screening techniques used and the preliminary identification of glutathione S-transferase M1 (GSTM1), as a gene that may be upregulated by Myb in ERMYB cells, have been described previously (Bartley et al., 2001) . Figure 1a ,b shows duplicate filters bearing GSTM1 cDNA that were probed with radiolabelled cDNA prepared either from ERMYB cells grown continually in b-estradiol, or from ERMYB cells grown in the absence of b-estradiol for 24 h. In each case, the level of GSTM1 mRNA is significantly higher in cells grown in the presence of estrogen and, therefore, active Myb. Northern blot analysis was performed to confirm that GSTM1 was a target for Myb regulation in this cell line (Figure 1c ). PolyA þ RNA was prepared from ERMYB cells grown In all cases (a-e) radioactivity was detected and quantitated using a PhosphorImager with ImageQuant software (Molecular Dynamics) in the absence of b-estradiol for varying periods of time, as indicated. In addition, in order to examine whether GSTM1 mRNA levels could be reinduced upon reactivation of Myb, RNA was also prepared from cells treated with b-estradiol for 24 h and after an absence of 24 h. The Northern blot was probed for GSTM1 and with GAPDH for standardization. Figure 1c shows that the level of GSTM1 mRNA decreased with time in the absence of active Myb protein and was reinduced to normal levels 24 h after Myb reactivation. Closer examination of the kinetics of GSTM1 reinduction (Figure 1d ) shows that following b-estradiol removal for 24 h, increased levels of GSTM1 mRNA were clearly detectable as early as 3 h after readdition and that steady-state levels were reached by 9 h. This rapid reinduction renders it highly unlikely that the observed effects of Myb activity are due to modulation of an intermediate factor, and strongly supports direct regulation of GSTM1 by Myb. To ensure that Myb activity, and not estrogen per se, was responsible for changes in GSTM1 levels, mRNA levels were examined in the CT3 Myb cell line that expresses an activated Myb protein that is not dependent on estrogen for activity (Macmillan and Gonda, 1994) . Northern analysis showed no significant difference in the level of GSTM1 in cells treated with either b-estradiol or the b-estradiol antagonist (Figure 1e ). (The small (60%) increase in GSTM1 mRNA seen in both treatments compared to the untreated cells may be due to upregulation of GST by the ethanol carrier (Vanhaecke et al., 2000) ).
To provide further evidence that GSTM1 is a direct target of Myb regulation, we undertook an analysis of the GSTM1 promoter. The availability of the murine GSTM1 promoter sequence (Figure 2a ; Reinhart and Pearson, 1993) enabled the PCR amplification of this region from mouse genomic DNA. Seven single-nucleotide differences were observed between the database entry and the sequence of our PCR product (Figure 2a ), Three potential, albeit imperfect, Myb-binding sites (MBS) were identified in this sequence (Figure 2 ). To determine whether the GSTM1 promoter was responsive to Myb, nucleotides À600 to þ 34 ( Figure 2a) were cloned into the pXPG luciferase reporter vector (Bert et al., 2000) and assayed for activity in murine NIH 3T3 fibroblasts, which do not express endogenous Myb. The resultant construct, pXPG-mGST (Figure 2c ), was substantially more active than the promoterless pXPG vector (Figure 3a) . Cotransfection of pXPG-mGST with increasing amounts of Myb expression plasmid (pactMyb; Nishina et al., 1989) resulted in an increase in luciferase activity of up to 2.5-fold. Further evidence for Myb regulation was provided by cotransfection with pactMybL3,4P, which encodes an activated mutant Myb that has previously been shown to possess higher transactivating (and transforming) ability than wildtype Myb . As expected, the GSTM1 promoter showed increased activity (5-6-fold over basal levels) in the presence of MybL3,4P. Cotransfection of Myb or MybL3,4P with the empty pXPG vector, however, showed no Figure 2 Promoter sequence of the murine GSTM1 gene. (a) Sequence of the GSTM1 proximal promoter region (GenBank Accession Number L13448; Reinhart and Pearson, 1993) . The exonic region is shown in bold, the transcription start site is at þ 1 and the translation initiation codon (ATG) is underlined. Boxed sequences define putative MBS. Nucleotide differences between the sequence cloned here and database entry are indicated by (*). (b) Sequence of putative MBS (with the core AAC (GTT) motif underlined) located in the murine GSTM1 promoter. These MBS were mutated to the sequences shown in the righthand column of the table (QuikChange TM site-directed mutagenesis, Stratagene) to generate the constructs shown in (c). (c) Schematic illustrating the pXPG-mGST constructs used in transactivation studies. The promoter region (nt À600 to þ 34) was PCR-amplified from mouse genomic DNA (oligonucleotides: 5 0 -GGATCGATCAGATCTGGT-GTTCCATGTCACCGACT-3 0 and 5 0 -GGATCGAT-CAAGCTTGCTGGTGCTGTGGTCTTCTC-3 0 ; conditions: 941C/2 min, followed by 941C/30 s, 601C/30 s, 721C/ 60 s for 35 cycles). Following digestion with HindIII and BglII (cleavage sites underlined), the insert was cloned upstream of the Luciferase reporter gene in BglII/HindIIIdigested pXPG, to generate the construct pXPG-mGST. X indicates mutation of the putative MBS to the sequence shown in (b) Figure 3 Myb activates the GSTM1 promoter through the proximal MBS 3 site. (a) Luciferase reporter assays in NIH 3T3 cells transfected with promoterless pXPG (150 ng; first lane only) or pXPG-GST (150 ng) and pact expression constructs of Myb, MybL3,4P, MybDDBD, MybDTA or MybL3,4PDDBD (0-200 ng as indicated). All samples were cotransfected with pcDNA3-SEAP (secreted alkaline phosphatase reporter construct; 300 ng) as a control for transfection efficiency. Total DNA transfected was made up to 800 ng using pact vector. Transfections were performed using Fugene 6 (Roche). At 48 h post-transfection, media were harvested for SEAP assays (Berger et al., 1988) and cells were lysed for luciferase assays (Passive Lysis Buffer; Promega). Luciferase activity was normalized for transfection efficiency; all experiments were performed at least three times (each in triplicate). Data from a representative experiment are shown as fold activation (7s.e.) over pXPG-GST alone. appreciable activation, indicating that Myb was acting on the GSTM1 promoter rather than on other elements of the reporter construct (Figure 3a, inset) .
To demonstrate that the promoter activation observed was dependent on Myb's DNA binding and transactivation functions, cotransfection studies were performed with several mutants of Myb. Neither MybDDBD nor MybL3,4PDDBD, in which the DNAbinding domain was deleted (Sakura et al., 1989) was capable of activating the GSTM1 promoter, implying that binding of Myb to the promoter is required for transactivation (Figure 3a) . Similarly, MybDTA, which lacks the acidic region required for transactivation (Sakura et al., 1989) , failed to increase GSTM1 promoter activity (Figure 3a) .
To determine which of the putative MBS located in the promoter of the GSTM1 gene were responsible for the Myb-induced promoter activation, these sites were mutated (Figure 2b, c) and the resulting constructs were tested for activation by Myb and MybL3,4P. As shown in Figure 3b , mutation of MBS 1 and MBS 2 had no effect on promoter activation. However, mutation of MBS 3 (either separately or in combination with the other two putative MBS, i.e. MBS 123) resulted in almost complete loss of Myb-induced promoter activation. Comparison of the mutant and wild-type promoters (Figure 3b , inset) demonstrated that the mutations had little effect on promoter activity in the absence of Myb.
Finally, we wished to demonstrate directly that Myb could bind to the functional MBS of the GSTM1 promoter. Electrophoretic mobility gel shift analysis (EMSA) was performed using a baculovirus-expressed, carboxyl-truncated form of Myb (CTLMyb; Ramsay et al., 1995) . EMSA indicated that Myb protein was able to bind to an oligonucleotide spanning MBS 3 (position À20 to À25), and this complex increased in intensity with increasing amounts of recombinant protein (Figure 4, lanes 1-3) . The mobility of this complex was identical to that of a complex formed using a canonical MBS oligonucleotide (data not shown), but as expected, control insect cell extracts lacking recombinant Myb failed to generate complexes of similar mobility with either the canonical MBS oligonucleotide or the MBS 3 oligonucleotide (data not shown). However, recombinant Myb protein was unable to bind to a similar oligonucleotide in which MBS 3 had been mutated (Figure 4, lanes 4-6) . Moreover, Myb binding to MBS 3 wild-type oligonucleotide could be competed with an MBS consensus oligonucleotide, but not a mutated MBS oligonucleotide (Figure 4 , lanes 7-9), demonstrating that Myb protein binds specifically to MBS 3 in the GSTM1 promoter. In contrast, Myb did not bind specifically to oligonucleotides corresponding to MBS1 (nucleotides À567 to À572) or MBS 2 (nucleotides À447 to À453; data not shown).
Taken together, the evidence presented here supports the notion that the gene encoding the detoxification enzyme GSTM1 is transcriptionally activated by c-Myb. Recently, the promoter of GSTM2, another member of the mu subclass, was also reported to be Myb-responsive, in that transcription was enhanced by a truncated form of Myb (Kumar and Reddy, 2001) .
What might be the physiological significance of Myb regulation of GSTM1 (and GSTs in general)? Many hemopoietic cells require cytokines for survival, growth and proliferation. Cytokine signalling is known to Figure 4 Recombinant Myb protein binds specifically to MBS 3 of the GSTM1 promoter. Increasing amounts of recombinant CTLMyb protein (1-4 ml; Ramsay et al., 1995) were added to a double-stranded oligonucleotide (0.5 ng) encompassing MBS 3 (5 0 -GTATAAAGTCACAACTCCAAACACACAGGTC-3 0 : core MBS underlined; lanes 1-3), or a double-stranded oligonucleotide (0.5 ng) containing a mutation in MBS 3 (5 0 -GTATAAAGT-CACGCGTCCAAACACACAGGTC-3 0 ; mutated MBS underlined; lanes 4-6) for 20 min in 25 mM Tris pH 8, 50 mM NaCl, 5 mM EDTA, 1 mM DTT, 1 mM PMSF, 1 mg poly (dI-dC) and 10 mg BSA. Reactions were electrophoresed on a 10% nondenaturing polyacrylamide gel in 0.5 Â TBE. Gels were dried and exposed to X-ray film. Competition experiments (lanes 7-9) were performed as above except that 50 ng of unlabelled consensus MBS oligonucleotides ; double-stranded competitor oligonucleotides: wild type 5 0 -CTCGAGAATGTGTCAGTTAGGGTGT-3 0 : mutant 5 0 -CTCGAGAATGTGTCAGCTAGGGTGT-3 0 ) were added during the incubation as indicated. X, nonspecific complexes induce the formation of reactive oxygen species (ROS; Sattler et al., 1999) which are potentially toxic. As GST family members have been shown to catalyse the elimination of ROS (Lavoie et al., 1992) , it is feasible that one role of Myb in normal hemopoietic cell function is to upregulate GSTM1 and GSTM2 in order to remove damaging ROS generated by cytokine signalling. More generally, many studies have shown that an increase in GSTM1 expression leads to an increased tolerance of cells to toxic xenobiotics and probably to potentially toxic metabolites (reviewed in Hayes and Pulford, 1995) . Thus, Myb regulation of GSTM1 may coordinate its expression with rapid proliferation, that is, with conditions under which cells generate more toxic metabolites and/or may be more sensitive to these. Furthermore, this increased tolerance is likely to extend to many cytotoxic drugs and thus may increase the resistance of Myb-expressing tumors to chemotherapy. Finally, Cho et al. (2001) have recently shown that GSTM1 inhibits apoptosis signal-regulating kinase 1 (Ask-1), a protein kinase that regulates certain mitogen-activated protein kinases and mediates apoptosis in response to cellular stress. This suggests an additional, but similarly protective, role for GSTM1, as the effect on Ask-1 was shown to be independent of its enzymatic activity.
